Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study

ARTAÇ, MEHMET; COŞKUN, HASAN; Korkmaz, Levent; Kocer, Murat; Turhal, Nazim; ENGİN, HÜSEYİN; Dede, Isa; PAYDAŞ, SEMRA; Oksuzoglu, Berna; Bozcuk, Hakan; DEMİRKAZIK, AHMET

doi:10.1016/j.clgc.2016.04.021

Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study

Atıf İçin Kopyala

ARTAÇ M., COŞKUN H. Ş. , Korkmaz L., Kocer M., Turhal N. S. , ENGİN H., ...Daha Fazla

CLINICAL GENITOURINARY CANCER, cilt.14, sa.4, 2016 (SCI İndekslerine Giren Dergi)

Cilt numarası: 14 Konu: 4
Basım Tarihi: 2016
Doi Numarası: 10.1016/j.clgc.2016.04.021
Dergi Adı: CLINICAL GENITOURINARY CANCER

Özet

Survival outcomes of interferon-alfa and tyrosine kinase inhibitors for 104 cases of metastatic renal cell carcinoma were included in this study. First-line interferon-alfa treatment before tyrosine kinase inhibitors had an additive survival affect.